FDA GFI, Definitions of Suspect Product & Illegitimate Product for Verification Obligations DSCSA, 03/23 Anastasija Eschricht2023-07-24T13:51:26+00:00July 24th, 2023|
PIC/S Aide-Memoire Inspection GDP for Medicinal Products in the Supply Chain, 02/23 Anastasija Eschricht2023-03-21T12:53:00+00:00March 21st, 2023|
EMA Questions and Answers: GDP Requirements (Updated Jan 2023) Anastasija Eschricht2023-03-21T12:43:11+00:00March 21st, 2023|
CAMD Q&A on Certificates of Free Sale and Article 60 of Regulation (EU) 2017/745, 06/22 Beatrice Burtsov2022-11-09T09:12:32+00:00November 9th, 2022|
EMA Guideline on responsibilities of sponsor with regard to handling and shipping of investigational medicinal products for human use in accordance with GCP and GMP Beatrice Burtsov2022-10-05T11:26:37+00:00October 4th, 2022|
FDA GFI, DSCSA Standards for Exchange of Information Tracing of Certain Human, Finished, Prescription Drugs, DRAFT, 07/22 Beatrice Burtsov2022-09-07T05:03:40+00:00September 7th, 2022|
